Printzis S, Raptopoulou-Gigi M, Orphanou-Koumerkeridou H, Lagre F, Goulis G
2nd Medical Department, Aristotelian University, Thessaloniki, Greece.
Immunopharmacol Immunotoxicol. 1994 Nov;16(4):679-93. doi: 10.3109/08923979409019745.
Thirty two anergic patients with chronic brucellosis treated with a) interferon-alpha 2b(group 1), b) levamisole (group 2) and c) conventional therapy(group 3) were studied. The effect of treatment on T lymphocyte blast formation in the presence of PHA, specific cell mediated immunity against brucella antigens, titers of brucella antibodies and clinical symptoms were evaluated .T lymphocyte blast formation was shown to range in normal levels in all patients before treatment compared to 10 normal controls suggesting against a generalized impairment of cell mediated immunity. Titers of brucella antibodies were significantly decreased in group 1, almost significantly in group 2 and were significantly increased in group 3 at the end of treatment. A significant improvement of symptoms as well as production of leukocyte migration inhibition against brucella antigens were noted in both groups 1 and 2, in contrast to group 3. This response to treatment was however greater in group 1. These findings demonstrate that immunotherapy resulted in both clinical and immunological improvement and that interferon seems to be a more promising therapeutic approach of chronic brucellosis.
对32例慢性布鲁氏菌病无反应性患者进行了研究,这些患者分别接受了以下治疗:a)α-干扰素2b(第1组)、b)左旋咪唑(第2组)和c)传统疗法(第3组)。评估了治疗对在PHA存在下T淋巴细胞母细胞形成、针对布鲁氏菌抗原的特异性细胞介导免疫、布鲁氏菌抗体滴度以及临床症状的影响。与10名正常对照相比,所有患者治疗前的T淋巴细胞母细胞形成显示处于正常水平,这表明不存在细胞介导免疫的普遍损害。治疗结束时,第1组布鲁氏菌抗体滴度显著降低,第2组几乎显著降低,第3组则显著升高。与第3组相比,第1组和第2组的症状均有显著改善,并且针对布鲁氏菌抗原产生了白细胞迁移抑制。然而,第1组对治疗的反应更大。这些发现表明免疫疗法在临床和免疫方面均有改善,并且干扰素似乎是慢性布鲁氏菌病更有前景的治疗方法。